Adagen Related Published Studies
Research related to Adagen (Pegademase)
Pegademase bovine: replacement therapy for severe combined immunodeficiency disease. [1991.10]
Other possibly related research studies
Role of endogenous adenosine in the acute and late response to allergen challenge in actively sensitized Brown Norway rats. [2003.07]
Chondroosseous dysplasia in severe combined immunodeficiency due to adenosine deaminase deficiency (chondroosseous dysplasia in ADA deficiency SCID). [1991]
Reduced thymic output, increased spontaneous apoptosis and oligoclonal B cells in polyethylene glycol-adenosine deaminase-treated patients. [2005.11]
Cerebral lymphoma in an adenosine deaminase-deficient patient with severe combined immunodeficiency receiving polyethylene glycol-conjugated adenosine deaminase. [2005.12]
Adenosine mediates IL-13-induced inflammation and remodeling in the lung and interacts in an IL-13-adenosine amplification pathway. [2003.08]
Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. [2003.04.01]
Development of pegylated interferons for the treatment of chronic hepatitis C. [2001]
Adenosine deaminase: functional implications and different classes of inhibitors. [2001.03]
The use of enzyme therapy to regulate the metabolic and phenotypic consequences of adenosine deaminase deficiency in mice. Differential impact on pulmonary and immunologic abnormalities. [2000.10.13]
In vitro and in vivo studies with human carrier erythrocytes loaded with polyethylene glycol-conjugated and native adenosine deaminase. [2000.06]
A girl with diabetes and severe combined immunodeficiency from adenosine deaminase deficiency. [1997.07]
T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. [1995.10.20]
Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients. [1995.10.20]
PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years. [1995.09]
Current status of orphan disease drug development. [1994.04]
Heterogeneity of phenotype in two siblings with adenosine deaminase deficiency. [1994.02]
Polymers for delivering peptides and proteins. [1994.01.15]
T lymphocyte ontogeny in adenosine deaminase-deficient severe combined immune deficiency after treatment with polyethylene glycol-modified adenosine deaminase. [1993.08]
Development of gene therapy for immunodeficiency: adenosine deaminase deficiency. [1993.01]
Enzyme replacement therapy with polyethylene glycol-adenosine deaminase in adenosine deaminase deficiency: overview and case reports of three patients, including two now receiving gene therapy. [1993.01]
[Polyethylene glycol-adenosine deaminase: a new adenosine deaminase deficiency therapy. Value of deoxyadenosine triphosphate determination for therapeutic monitoring] [1991.07]
[Cellular and molecular therapy in severe combined immunodeficiencies] [1991.03]
Adenosine deaminase deficiency with late onset of recurrent infections: response to treatment with polyethylene glycol-modified adenosine deaminase. [1988.08]
Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID). [2005.11]
Management options for adenosine deaminase deficiency; proceedings of the EBMT satellite workshop (Hamburg, March 2006). [2007.05]
Immunologic reconstitution during PEG-ADA therapy in an unusual mosaic ADA deficient patient. [2009.02]
The impact of PEGylation on biological therapies. [2008]
Adenosine signaling, priapism and novel therapies. [2009.03]
Hematopoietic stem cell gene therapy for adenosine deaminase deficient-SCID. [2009]
|
